2015, ISBN 9788865703007, 227
Book
2002, ISBN 8871793587, 252
Book
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 2, pp. 122 - 137
At 8 years of follow-up, premenopausal women with breast cancer had higher rates of disease-free and overall survival with the addition of ovarian suppression...
MEDICINE, GENERAL & INTERNAL | OVARIAN-FUNCTION SUPPRESSION | REPORTED OUTCOMES | RANDOMIZED-TRIALS | TAMOXIFEN | POPULATION-BASED COHORT | OOPHORECTOMY | PATIENT-LEVEL METAANALYSIS | TEXT | YOUNG-WOMEN | SOFT TRIALS | Breast Neoplasms - surgery | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Premenopause | Humans | Middle Aged | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Young Adult | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Adult | Female | Androstadienes - therapeutic use | Receptor, ErbB-2 | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Women | Care and treatment | Usage | Hormone therapy | Analysis | Breast cancer | Health aspects | Medical research | Oncology | Tamoxifen | Cancer therapies | Survival | ErbB-2 protein | Studies | Design | Chemotherapy | Hospitals | Womens health | Aromatase | Drug dosages
MEDICINE, GENERAL & INTERNAL | OVARIAN-FUNCTION SUPPRESSION | REPORTED OUTCOMES | RANDOMIZED-TRIALS | TAMOXIFEN | POPULATION-BASED COHORT | OOPHORECTOMY | PATIENT-LEVEL METAANALYSIS | TEXT | YOUNG-WOMEN | SOFT TRIALS | Breast Neoplasms - surgery | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Premenopause | Humans | Middle Aged | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Young Adult | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Adult | Female | Androstadienes - therapeutic use | Receptor, ErbB-2 | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Women | Care and treatment | Usage | Hormone therapy | Analysis | Breast cancer | Health aspects | Medical research | Oncology | Tamoxifen | Cancer therapies | Survival | ErbB-2 protein | Studies | Design | Chemotherapy | Hospitals | Womens health | Aromatase | Drug dosages
Journal Article
European journal of human genetics, ISSN 1018-4813, 2013, Volume 21, Issue 10, pp. 1074 - 1078
Joubert syndrome and related disorders (JSRD) are clinically and genetically heterogeneous ciliopathies sharing a peculiar midbrain-hindbrain malformation...
Joubert syndrome and related disorders | ciliopathies | Meckel syndrome | INPP5E | RETINAL DEGENERATION | MODIFIER | FORM | COACH SYNDROME | CILIUM | BIOCHEMISTRY & MOLECULAR BIOLOGY | RPGRIP1L | AHI1 | MECKEL | GENETICS & HEREDITY | REVEALS | Polycystic Kidney Diseases - genetics | Kidney Diseases, Cystic - diagnosis | Polycystic Kidney Diseases - diagnosis | Prevalence | Humans | Child, Preschool | Molecular Sequence Data | Infant | Male | Cerebellum - abnormalities | Retinitis Pigmentosa | Kidney Diseases, Cystic - genetics | Female | Child | Encephalocele - genetics | Amino Acid Sequence | Encephalocele - diagnosis | Eye Abnormalities - diagnosis | Phosphoric Monoester Hydrolases - genetics | Cerebellar Diseases - diagnosis | Gene Frequency | Prenatal Diagnosis | Abnormalities, Multiple | Eye Abnormalities - genetics | Phenotype | Cerebellar Diseases - genetics | Pedigree | Adolescent | Retina - abnormalities | Ciliary Motility Disorders - diagnosis | Heterozygote | Mutation | Ciliary Motility Disorders - genetics | Brain | Pediatrics | Neurosciences | Meckel's syndrome | Retinopathy | Kidneys | Mesencephalon | Laboratories | Congenital defects | Genes | Fetuses | Liver | Teeth | Neurodevelopmental disorders | Medicine | Neurology | Hospitals | Genetics | Hindbrain
Joubert syndrome and related disorders | ciliopathies | Meckel syndrome | INPP5E | RETINAL DEGENERATION | MODIFIER | FORM | COACH SYNDROME | CILIUM | BIOCHEMISTRY & MOLECULAR BIOLOGY | RPGRIP1L | AHI1 | MECKEL | GENETICS & HEREDITY | REVEALS | Polycystic Kidney Diseases - genetics | Kidney Diseases, Cystic - diagnosis | Polycystic Kidney Diseases - diagnosis | Prevalence | Humans | Child, Preschool | Molecular Sequence Data | Infant | Male | Cerebellum - abnormalities | Retinitis Pigmentosa | Kidney Diseases, Cystic - genetics | Female | Child | Encephalocele - genetics | Amino Acid Sequence | Encephalocele - diagnosis | Eye Abnormalities - diagnosis | Phosphoric Monoester Hydrolases - genetics | Cerebellar Diseases - diagnosis | Gene Frequency | Prenatal Diagnosis | Abnormalities, Multiple | Eye Abnormalities - genetics | Phenotype | Cerebellar Diseases - genetics | Pedigree | Adolescent | Retina - abnormalities | Ciliary Motility Disorders - diagnosis | Heterozygote | Mutation | Ciliary Motility Disorders - genetics | Brain | Pediatrics | Neurosciences | Meckel's syndrome | Retinopathy | Kidneys | Mesencephalon | Laboratories | Congenital defects | Genes | Fetuses | Liver | Teeth | Neurodevelopmental disorders | Medicine | Neurology | Hospitals | Genetics | Hindbrain
Journal Article
2008, Architetti e architetture, ISBN 8837057466, Volume 23, 141
Book
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
This trial did not support routine use of ovarian suppression in premenopausal breast cancer. Nevertheless, there may be some benefit from ovarian suppression...
AMENORRHEA | MEDICINE, GENERAL & INTERNAL | THERAPY | YOUNG-WOMEN | CHEMOTHERAPY | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogen | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
AMENORRHEA | MEDICINE, GENERAL & INTERNAL | THERAPY | YOUNG-WOMEN | CHEMOTHERAPY | Breast Neoplasms - surgery | Premenopause | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Mastectomy | Adult | Female | Androstadienes - therapeutic use | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Chemotherapy | Womens health | Invasiveness | Estrogen | Population studies | Breast cancer | Reproductive system | Tamoxifen | Drug therapy | Survival | Patients | Statistical analysis | Endocrine therapy | Radiation therapy | Cancer therapies | Survival analysis | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Aromatase inhibitors are somewhat more effective than tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. This benefit was extended...
TRIAL | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | TAMOXIFEN | SEQUENCE | LETROZOLE | ENDOCRINE THERAPY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | AMERICAN-SOCIETY | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase
TRIAL | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | TAMOXIFEN | SEQUENCE | LETROZOLE | ENDOCRINE THERAPY | FOLLOW-UP | POSTMENOPAUSAL WOMEN | AMERICAN-SOCIETY | Estradiol - blood | Breast Neoplasms - surgery | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Aromatase Inhibitors - therapeutic use | Osteoporosis - chemically induced | Premenopause | Kaplan-Meier Estimate | Triptorelin Pamoate - adverse effects | Triptorelin Pamoate - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Quality of Life | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Care and treatment | Breast cancer | Research | Ovariectomy | Invasiveness | Radiation | Clinical trials | Data processing | Pituitary (anterior) | Gonadotropins | Tamoxifen | Survival | Patients | Clinical outcomes | Post-menopause | Chemotherapy | Aromatase
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2014, Volume 32, Issue 18_suppl, pp. LBA1 - LBA1
LBA1 Background: Adjuvant endocrine therapy with AI vs T improves outcomes in postmenopausal HR+ BC. TEXT and SOFT were designed to test whether adjuvant AI...
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. LBA1 - LBA1
Journal Article
10.
Full Text
Eyes on K2-3: A system of three likely sub-Neptunes characterized with HARPS-N and HARPS
Astronomy and Astrophysics, ISSN 0004-6361, 07/2018, Volume 615, p. A69
Context. M-dwarf stars are promising targets for identifying and characterizing potentially habitable planets. K2-3 is a nearby (45 pc), early-type M dwarf...
Stars: individual: K2-3 | Techniques: radial velocities | Planets and satellites: detection | Stars: individual: EPIC 201367065 | Stars: individual: 2MASS 11292037-0127173 | Planets and satellites: composition | PLANETS | techniques: radial velocities | SPACE TELESCOPE | MISSION | planets and satellites: composition | stars: individual: 2MASS 11292037-0127173 | SUPER-EARTH | CANDIDATE | KEPLER | M DWARFS | STAR | PHOTOMETRY | EXOPLANETS | ASTRONOMY & ASTROPHYSICS | planets and satellites: detection | stars: individual: K2-3 | stars: individual: EPIC 201367065 | Bulk density | Computer simulation | Time series | Orbits | Regression analysis | Velocity | Stellar models | Red dwarf stars | Planets | Gaussian process | Spectrographs | Planet detection | Moisture content | Water content | Weights & measures | Stellar rotation | Radial velocity | Stellar activity | Planetary rotation | Physics - Earth and Planetary Astrophysics
Stars: individual: K2-3 | Techniques: radial velocities | Planets and satellites: detection | Stars: individual: EPIC 201367065 | Stars: individual: 2MASS 11292037-0127173 | Planets and satellites: composition | PLANETS | techniques: radial velocities | SPACE TELESCOPE | MISSION | planets and satellites: composition | stars: individual: 2MASS 11292037-0127173 | SUPER-EARTH | CANDIDATE | KEPLER | M DWARFS | STAR | PHOTOMETRY | EXOPLANETS | ASTRONOMY & ASTROPHYSICS | planets and satellites: detection | stars: individual: K2-3 | stars: individual: EPIC 201367065 | Bulk density | Computer simulation | Time series | Orbits | Regression analysis | Velocity | Stellar models | Red dwarf stars | Planets | Gaussian process | Spectrographs | Planet detection | Moisture content | Water content | Weights & measures | Stellar rotation | Radial velocity | Stellar activity | Planetary rotation | Physics - Earth and Planetary Astrophysics
Journal Article
Experimental Astronomy, ISSN 0922-6435, 2014, Volume 38, Issue 1-2, pp. 249 - 330
PLATO 2.0 has recently been selected for ESA’s M3 launch opportunity (2022/24). Providing accurate key planet parameters (radius, mass, density and age) in...
Statistics for Engineering, Physics, Computer Science, Chemistry and Earth Sciences | Transit survey | Stellar science | Asteroseismology | Physics | Exoplanets | Exoplanetary science | Astronomy, Observations and Techniques | SPIN-ORBIT MISALIGNMENT | P-MODE MEASUREMENTS | ANGULAR-MOMENTUM TRANSPORT | TRANSIT TIMING OBSERVATIONS | DELTA-SCUTI STARS | PRE-MAIN-SEQUENCE | GIANT PLANET FORMATION | ASTRONOMY & ASTROPHYSICS | ENERGETIC NEUTRAL ATOMS | MASS-RADIUS RELATIONSHIPS | SOLAR-TYPE STARS | Discovery and exploration | Usage | Equipment and supplies | Space probes | Outer space | Planets | Planet detection | European Space Agency | Stars | Catalogues | Mathematical models | Density | Age | Physics - Earth and Planetary Astrophysics | Fysik | Physical Sciences | Astronomi, astrofysik och kosmologi | Naturvetenskap | Natural Sciences | Astronomy, Astrophysics and Cosmology
Statistics for Engineering, Physics, Computer Science, Chemistry and Earth Sciences | Transit survey | Stellar science | Asteroseismology | Physics | Exoplanets | Exoplanetary science | Astronomy, Observations and Techniques | SPIN-ORBIT MISALIGNMENT | P-MODE MEASUREMENTS | ANGULAR-MOMENTUM TRANSPORT | TRANSIT TIMING OBSERVATIONS | DELTA-SCUTI STARS | PRE-MAIN-SEQUENCE | GIANT PLANET FORMATION | ASTRONOMY & ASTROPHYSICS | ENERGETIC NEUTRAL ATOMS | MASS-RADIUS RELATIONSHIPS | SOLAR-TYPE STARS | Discovery and exploration | Usage | Equipment and supplies | Space probes | Outer space | Planets | Planet detection | European Space Agency | Stars | Catalogues | Mathematical models | Density | Age | Physics - Earth and Planetary Astrophysics | Fysik | Physical Sciences | Astronomi, astrofysik och kosmologi | Naturvetenskap | Natural Sciences | Astronomy, Astrophysics and Cosmology
Journal Article